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Abstract: OBJECTIVE The objective of this prospective study was to evaluate right ventricular function
and pulmonary arterial compliance (PAC=stroke volume/pulse pressure) at rest and during exercise in
patients with systemic sclerosis (SSc) with normal mean pulmonary artery pressures (mPAP) at rest,
mildly elevated mPAP (mPAP 21-24mmHg) and manifest pulmonary hypertension (mPAP฀25mmHg).
METHODS Patients with SSc (n=112) underwent clinical assessment and right heart catheterization
at rest and during exercise and were divided into three groups according to their resting mPAP val-
ues: normal mPAP (฀20mmHg), mildly elevated mPAP (21-24mmHg) and pulmonary hypertension (PH,
mPAP ฀25mmHg). Results were compared between groups by ANOVA followed by post-hoc student’s
t-test. RESULTS Compared to patients with normal mPAP, patients with mildly elevated mPAP showed
lower 6-minute-walking distance (6MWD; p<0.008), lower cardiac index (CI) (p=0.027) and higher PVR
(p=0.0002) during exercise and lower PAC at rest (p=0.016) and different stages of exercise (25 Watts
p=0.033, 75 Watts p=0.024). CONCLUSION The results of this study suggest that impaired 6MWD in
SSc-patients with mildly elevated mPAP might be caused by reduced PAC during exercise and reduced
RV output reserve, presumably due to impaired coupling between the right ventricle and the pulmonary
vasculature. These findings give further evidence for the clinical relevance of mildly elevated mPAP in
patients with SSc. This article is protected by copyright. All rights reserved.
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The objective of this prospective study was to evaluate right ventricular function and 
pulmonary arterial compliance (PAC=stroke volume/pulse pressure) at rest and during 
exercise in patients with systemic sclerosis (SSc) with normal mean pulmonary artery 
pressures (mPAP) at rest, mildly elevated mPAP (mPAP 21-24mmHg) and manifest 
pulmonary hypertension (mPAP25mmHg). 
Methods: 
Patients with SSc (n=112) underwent clinical assessment and right heart catheterization at 
rest and during exercise and were divided into three groups according to their resting mPAP 
values: normal mPAP (≤20mmHg), mildly elevated mPAP (21-24mmHg) and pulmonary 
hypertension (PH, mPAP ≥25mmHg). Results were compared between groups by ANOVA 
followed by post-hoc student’s t-test.  
Results: 
Compared to patients with normal mPAP, patients with mildly elevated mPAP showed lower 
6-minute-walking distance (6MWD; p<0.008), lower cardiac index (CI) (p=0.027) and higher 
PVR (p=0.0002) during exercise and lower PAC at rest (p=0.016) and different stages of 
exercise (25 Watts p=0.033, 75 Watts p=0.024).  
Conclusion: 
The results of this study suggest that impaired 6MWD in SSc-patients with mildly elevated 
mPAP might be caused by reduced PAC during exercise and reduced RV output reserve, 
presumably due to impaired coupling between the right ventricle and the pulmonary 
vasculature. These findings give further evidence for the clinical relevance of mildly elevated 
mPAP in patients with SSc.  














The natural course of systemic sclerosis (SSc) is often complicated by the occurrence of 
pulmonary arterial hypertension (PAH)(1, 2). Patients with SSc-associated pulmonary arterial 
hypertension (SSc-PAH) have a lower survival rate compared to patients with idiopathic PAH 
(IPAH)(3, 4). The current haemodynamic definition of PAH is a resting mean pulmonary 
arterial pressure (mPAP) ≥25 mmHg with elevated pulmonary vascular resistance (PVR) 
measured invasively by right heart catheter (RHC)(7, 8).  A post-hoc analysis of the DETECT 
study on SSc-patients demonstrated that mildly elevated mPAP levels between 21 and 24 
mmHg may represent an intermediate stage between normal mean pulmonary artery 
pressures (<21mmHg) at rest and manifest PH (9). Previous studies have shown that 
patients with mildly elevated mPAP have reduced exercise capacity, higher World Health 
Organisation (WHO) functional class (FC)(6, 10), a high risk of developing manifest PH (11), 
and an impaired prognosis (1). However, the pathophysiological mechanisms underlying 
exercise intolerance in mPAP 21-24mmHg remain incompletely characterized. 
In the current study we sought to evaluate the response of the right ventricle (RV) and 
pulmonary vasculature to exercise in three different groups of SSc-patients: mPAP 
<21mmHg (normal resting mPAP), mPAP 21-24mmHg (formerly borderline-mPAP) and 
mPAP ≥ 25mmHg (manifest pulmonary hypertension). The question was whether these three 
groups show significant differences in right ventricular output reserve measured by an 
increase in cardiac index (CI) under exercise and pulmonary arterial compliance (PAC) 
measured by Swan-Ganz right heart catheter (RHC) in routine clinical practice. RV output 
reserve is an emerging parameter which has shown to be of prognostic importance in 
patients with PH(15, 16).For estimation of PAC (or capacitance) the measurement of stroke 
volume/pulse pressure (cardiac output/heart rate)/(systolicPAP-diastolicPAP) by RHC has 
been shown to be the most simple and practical method(17, 18).Furthermore RV output 
reserve and PAC may add crucial information to detect pulmonary vascular disease in this at-
risk-population at an early stage (13, 14), which may also add to defining an indication for 
early targeted treatment.  















Study population and design 
Patients affected by diffuse cutaneous SSc (dc-SSc) and limited cutaneous SSc (lc-SSc) 
referred to our centre for the purpose of PH screening were prospectively and consecutively 
enrolled in this study between October 2012 and August 2016. The referring specialists were 
rheumatologists, cardiologists, pulmonologists and general practitioners. Definite diagnosis 
of SSc was confirmed by experienced rheumatologists (HL, NB, CF) according to the 
standard criteria of the American College of Rheumatology (19). Exclusion criteria were: 
inability to perform exercise RHC, manifest PH confirmed by RHC prior to enrolment, 
receiving PAH therapy, renal insufficiency, systemic arterial hypertension with pressure 
values >180/95 mmHg at rest or >230/120 mmHg during exercise despite optimized medical 
treatment, previous evidence of clinically relevant left heart or lung disease or pregnancy.  
All patients who were referred to our centre who did not fulfil exclusion criteria were entered 
into the study even if baseline Echo did not suggest PH 
All patients underwent a detailed clinical work-up including medical history, physical 
examination, electrocardiogram, 2-Dimensional-echocardiography at rest, lung function test, 
arterial blood gases, chest X-ray, functional class (FC) assessment, 6-minute walking 
distance (6MWD) under standardized conditions (20), laboratory testing including N-terminal 
pro brain natriuretic peptide (NTpro-BNP) levels, and RHC at rest and during exercise. 12-
lead electrocardiogram was performed in all patients (Hellige EK 512 P, Hellige, Germany). 
High resolution computed tomography (CT), ventilation/perfusion SPECT and CT 
angiography of the lungs were performed in all patients to diagnose/exclude patients with 
suspected chronic thromboembolic PH, interstitial lung disease, or other respiratory 
diseases. Left heart catheterization was performed in all patients with suspected left heart 
disease. Manifest PH/PAH was diagnosed according to the current ERS/ESC-guidelines (8). 
 













Definition of pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) 
PH and PAH were defined according to current ESC/ERS Guidelines (41). The 
haemodynamic definition for PH is mPAP ≥25mmHg, the definition for PAH (group 1 
according to WHO classification) is ≥25mmHg and pulmonary arterial wedge pressure 
(PAWP) ≤15mmHg. 
 
Right heart catheter (RHC) 
SSc patients were consecutively referred to RHC in in order to screen this at-risk-population 
for manifest PH. Patients were examined on a variable load supine bicycle ergometer (model 
8420; KHL Corp., Kirkland, Washington) by experienced investigators (CN, BE). The 
examination at rest was performed as previously described (1) in a supine position using the 
transjugular access with an 8F introducer set (MXI100, MEDEX, Smiths Group PLC, UK). 
Catheterization was done by triple-lumen 7F-Swan-Ganz thermodilution catheters by 
Edwards Lifesciences (REF:131F7, Edwards Lifesciences LLC, Irvine, CA, USA). After the 
hemodynamic measurement at rest, the supine position was changed to a 45° position. The 
zero reference point for pressure recordings was set at midchest at the insertion of the 4th rib 
to the sternum in line with current recommendations(21) on the left atrial level. Zero levelling 
at 45°position was performed at the intersection of the frontal plane at the midthoracic level, 
the transverse plane at the level of 4th anterior intercostal space and the midsagittal plane on 
the left atrial level(22). The pulmonary vascular pressures (mPAP, PAWP) were averaged 
throughout three respiratory cycles. Cardiac output (CO) was measured at least in triplicate 
at rest and in duplicate at the end of each workload step during exercise by thermodilution 
with a variation of <10% between the measured values. Exercise testing started at 25 W and 
was increased every 2 min for 25 W until symptom-limited exercise capacity was reached. 
The pulmonary vascular pressures (mPAP, PAWP), CO, heart rate and systemic blood 
pressure were measured at the end of each workload step(22) in line with current 
recommendations. 













Transpulmonary pressure gradient (TPG) was defined as the difference between mPAP and 
PAWP. PAC was calculated according the formula PAC=stroke volume/ pulse pressure; 
(CO/Heart rate)/(sPAP-dPAP). Right ventricular output reserve was defined and measured 
by the increase in cardiac index (CI) during incrementally increased exercise on the variable 
load supine bicycle ergometer compared to CI at rest. All examinations and measurements 
were performed by the same experienced team (CN, BE, SH). There were no complications. 
 
Transthoracic Doppler echocardiography at rest  
A complete left- and right-sided echocardiographic examination was done as described 
previously (14). Two-dimensional and colour-flow guided continuous-wave-Doppler-
echocardiographic recordings at rest were obtained by experienced cardiac sonographers 
(CN, BE, SH, EG) using 3.6-4 MHz Duplex probes and conventional equipment (Vivid 7, GE 
Healthcare, Milwaukee, Wisconsin) at rest as described before (14). Pulmonary arterial 
systolic pressure (PASP) was estimated from peak tricuspid regurgitation jet velocities 
according to the equation: PASP= 4 (V)2 + right atrial pressure, where V is the peak velocity 
(in m/s) of tricuspid regurgitation velocity (23). For all calculations the mean value of at least 
3 tricuspid regurgitation velocity measurements was used. Right atrial pressure was 
estimated from characteristics of the inferior vena cava (24). If it was <20mm in diameter and 




This study was conducted in accordance with Good Clinical Practice (GCP) and the current 
version of the revised Declaration of Helsinki (WMA Declaration of Helsinki). The ethics 
committee of the University of Heidelberg approved the study (Internal Ethics-Nr. S-
360/2009). The trial was registered in Clinicaltrials.gov (NCT01387035). Written informed 
consent was obtained from each patient prior to enrolment. 















Statistical analyses were conducted by two statisticians (CF, NB). Data are described as 
mean ± standard deviation or number and %, respectively. Patients were divided into three 
groups according to their resting mPAP values: normal mPAP (mPAP ≤20 mmHg), mildly 
elevated PAP (21-24 mmHg) and manifest PH (mPAP≥ 25 mmHg) (Figure 1). At rest, the 
three groups (normal mPAP, mildly elevated PAP and manifest PH) were compared using 
analysis of variance (ANOVA) for quantitative variables and Chi square tests or exact Fisher 
Tests for categorical variables. The comparison of variables at rest and various levels of 
exercise or maximum level of exercise between the three groups were performed by ANOVA 
and mixed model ANOVA, respectively. If the ANOVA detected a significant difference, 
results were followed by post-hoc tests between normal and mildly elevated mPAP. Post-hoc 
analyses were conducted with student’s t-tests. All tests were two-sided and a p-value of 
0.05 was considered statistically significant. For post-hoc tests, statistical significance 
remained when p-values were <0.016, <0.025 and <0.05 for the first, second and third p-
value when ordered from lowest to highest (Bonferroni-Holm correction).  
Correlation of PAC at rest with 6MWD, Δ CO and Δ CI was performed with Pearson 
correlation analysis.  
All analyses have been performed using IBM SPSS 23 (SPSS Statistics V23, IBM 





We prospectively included 116 patients diagnosed with SSc. Four patients were excluded 
due to inability to perform RHC. One patient refused RHC assessment due to painful skin. 
Three patients were not able to perform exercise RHC due to knee or hip problems. There 













were no complications. Thus, the final study group consisted of 112 patients with SSc (88 
females, mean age 57±13 years; 76 (67.9%) with dc-SSc and 36 (32.1%) with lc-SSc 
(CREST Syndrome) (Table 1). According to RHC measurements at rest, 72 patients 
presented with normal mPAP ≤20 mmHg (64.3%), 14 with mildly elevated mPAP (21- 
24mmHg; 12.5%) and 26 with manifest PH (mPAP≥ 25 mmHg; 23.2%, Figure 1).  
The patients with PH had been newly diagnosed during the study. Most of them had been 
diagnosed at a relatively early stage of disease with an mPAP of 32.5±7.2mmHg, a mean 
PVR of 326.2±188.3dynes·sec·cm-5´, and normal RV function at rest but with impaired WHO 
functional class and exercise capacity (Table 1). Out of the 26 PH-patients, 10 had PAH, 8 
PH due to left heart disease, and 8 PH due to lung disease. Out of 14 patients with mildly 
elevated mPAP, two had concomitant coronary artery disease and five had concomitant 
interstitial lung disease. 
 
Comparison of clinical parameters  
The three groups (normal mPAP, mildly elevated mPAP, manifest PH) differed in age, with 
manifest PH showing the highest mean age (normal mPAP 54.1±12.9 years, mildly elevated 
mPAP 58.1±11.0 years, manifest PH 66.7±9.3 years; ANOVA p<0.0001; table 1). The 
Modified Rodnan Skin Score (MRSS) also differed between groups with normal mPAP 
12.6±7.5, mildly elevated mPAP 20.3±11.2 and manifest PH 18.9±11.1 (ANOVA p=0.019; 
table 1). There were no significant differences between patients with normal and mildly 
elevated mPAP with regards to sex, body size, duration of SSc and FC (Table 1). A 
comparable prevalence of coronary artery disease (CAD), mild SSc associated interstitial 
lung disease and arterial hypertension was found among the three different groups.  
Although patients with mildly elevated mPAP had higher values of resting systolic blood 
pressure than those with normal mPAP (138.6±16.9mmHg vs. 120.1±15.1mmHg, p=0.001), 
the systolic blood pressures during maximum workload did not significantly differ to patients 
with normal mPAP at rest (156.9±22.8mmHg vs. 167.6±26.8mmHg, p>0.05; table 1). 
Furthermore, PAWP during exercise did not significantly differ between groups.  














The mean 6MWD significantly differed (ANOVA p<0.0001) between the three groups with 
lowest walking distance in the manifest PH group (342±87 meters), followed by patients with 
mildly elevated mPAP (396±87 meters) and highest walking distance in the normal mPAP 
group (474±79 meters; table 1). Patients with mildly elevated mPAP had a significantly lower 
mean 6MWD compared to the group with normal haemodynamics (p=0.008; table 1). 
The difference in exercise capacity could also be seen in a different peak workload (ANOVA 
p<0.001) with highest peak workload in patients with normal mPAP (76.7±21.9 Watts), and 
lowest peak workload in patients with manifest PH (51.9±19.9 Watts). Peak workload in 
patients with mildly elevated mPAP was lower than in patients with normal mPAP (mildly 
elevated mPAP 62.5±25.5 Watts; p=0.033). Patients with mildly elevated mPAP did not 
significantly differ from manifest PH in peak workload. 
 
Echocardiography 
The echo measurements showed no significant differences between patients with normal 
mPAP and mildly elevated mPAP regarding the size of the right atrium (RA) and the right 
ventricle (RV) as well as systolic function measured by tricuspid annular plane systolic 
excursion (TAPSE) and estimated pulmonary arterial systolic pressure (PASP) assessed by 
transthoracic Doppler echocardiography (TDE) at rest. As expected patients with manifest 
PH revealed larger RA (15.5±5.3cm2 vs. 11.6±3.2cm2, p=0.001) and RV area (17.9±4.2cm2 
vs. 14.8±3.8cm2, p=0.001) as well as a thicker RV free wall (7.5±1.3mm vs. 6.5±1.2mm, 
p=0.004) than patients with normal haemodynamics (table 1). Patients with mildly elevated 
mPAP at rest significantly differed from patients with manifest PH in RA area (p=0.004), RV 
area (p=0.003), sPAP (p<0.001) and RV free wall (p=0.016; table 1).  
 
Pulmonary haemodynamics at rest  
Patients with mildly elevated mPAP showed significantly higher mean pulmonary vascular 
resistance (PVR) at rest when compared with patients in the normal mPAP group (179±32 













vs. 117±45 dynes·sec·cm-5; p=0.001) (Table 2) and higher transpulmonary pressure gradient 
(TPG) (12.7±3 vs. 7.5±2.6 mmHg, p<0.0001; table 2). Values for PVR and TPG were 
significantly lower than in patients with manifest PH (p=0.001 and p<0.0001, table 2). 
Mean PAWP were within normal range in patients with normal mPAP, mildly elevated mPAP 
and manifest PH (Table 2). No differences were found regarding right atrial pressures (RAP), 
as well as RV function at rest (CO and CI at rest, ns) among all groups (table 2).  
 
Pulmonary haemodynamics during exercise  
Patients with mildly elevated mPAP reached significantly higher mean (mPAP) and systolic 
pulmonary pressures (sPAP) at peak workload compared to patients with normal mPAP at 
rest (37.4±6.3mmHg vs. 31.7±7.5mmHg, p<0.0001). Patients with mildly elevated mPAP had 
a significantly lower increase in CO and cardiac index (CI) during exercise than patients with 
normal mPAP (peak CI: 5.4±0.9 vs. 6.3±1.8 l/min·m-2, p=0.027; ΔCI 2.1±1.2 vs. 3.3±1.5 
l/min·m-2, p=0.006) (table 2) and did not significantly differ from patients with manifest PH.  
CI increases during exercise showed an almost congruent course in patients with mildly 
elevated mPAP and manifest PH up to the 50 Watts level (Figure 3). At 75 Watts, patients 
with mildly elevated mPAP patients showed a lower mean CI increase than patients with 
manifest PH (ANOVA three groups p=0.009; normal mPAP vs. mildly elevated mPAP 
p=0.005). Two patients with mildly elevated mPAP dropped their CI during exercise, one at 
25 and one at 50 Watts.  
 
Patients with mildly elevated mPAP had a significantly higher TPG than patients with normal 
mPAP for values at rest, 25 Watts (both p<0.001), 75 Watts (p=0.008) and showed a trend at 
50 Watts (p=0.059). The slope of TPG-increase during exercise was similar in patients with 
mildly elevated mPAP and normal mPAP. 
PAC significantly differed between the three groups at rest and for each workload (each 
p≤0.01). Patients with mildly elevated mPAP had a significantly lower PAC than patients with 
normal mPAP at rest (p=0.016), as well as at 25 (p=0.033) and 75 (p=0.024) Watts (Figure 













4). PAC at rest significantly correlated with 6MWD (R=0.448, p<0.001), Δ CO (R=0.227, 
p=0.018) and correlated in trend with Δ CI (R=0.178, p=0.064). 
 
Discussion 
To the best of our knowledge, this is the first prospective study assessing RV output reserve 
and PAC in SSc-patients with mildly elevated mPAP in comparison to SSc patients with 
normal mPAP at rest and SSc-patients with manifest PH. The study showed that SSc-
patients with mildly elevated mPAP had normal CI-values at rest but a reduced RV output 
reserve (defined as reduced CI during exercise) and a reduced PAC compared to SSc-
patients with normal mPAP at rest. Furthermore, the study revealed that SSc-patients with 
mildly elevated mPAP had higher PVR and TPG values than patients with normal mPAP. The 
impairment in RV function and pulmonary haemodynamics in patients with mildly elevated 
mPAP was associated with lower 6MWD and reduced peak exercise capacity compared to 
SSc patients with normal resting haemodynamics.  
 
Reduced RV output reserve in SSc-patients with mildly elevated mPAP 
Mean RV CI at rest was normal and did not differ between SSc-patients with normal or mildly 
elevated mPAP as previously described(6, 9, 25). Even right heart size (mean right atrial and 
ventricular areas) measured by echocardiography were comparable between both groups. 
Thus, reduced RV output reserve, reduced PAC and higher PVR and TPG were the only 
hemodynamic parameters characterizing patients with mildly elevated mPAP and might be 
the pathophysiological underpinning of symptoms and reduced 6MWD/exercise capacity in 
these patients. These data suggest that exercise haemodynamics might be more sensitive to 
early RV dysfunction and vascular remodeling than resting haemodynamics.  
RV output reserve and contractile reserve have been previously assessed in PAH patients 
using different methods and surrogate parameters: by invasive single-beat pressure-volume 
loop analysis(26-28), by stress Doppler-echocardiography (SDE) assessing the capability of 
patients to increase right ventricular systolic pressure during low-level exercise (14) and by 













echocardiographic strain during SDE (29). Although invasive single-beat pressure-volume 
loop analysis (30) is most likely the most sophisticated method to evaluate load-independent 
RV contractile reserve, its application can be dangerous for patients (stiff catheters), is too 
costly and complex for routine clinical practice and needs special equipment like 
conductance catheters with special software for online pressure-volume signals (30, 31) and 
transit-time ultrasonic flow probes (26). Therefore, the assessment of CI increase during 
exercise by RHC using Swan-Ganz catheters has been used in PAH patients before (15, 16) 
and has been performed in this study. It seems to be a simple and useful method to measure 
RV output reserve.  
 
Reduced PAC in mildly elevated mPAP might indicate early vascular remodelling  
Whereas RV function was impaired during exercise only, PAC was already significantly 
reduced at rest and during all exercise levels in patients with mildly elevated mPAP and PH-
patients compared to patients with normal mPAP (Figure 4). Decreased PAC has been 
described in patients with idiopathic PAH (18) and was correlated with PH severity (32). In 
the present study, PAC was calculated from RHC data and it has been shown that PAC may 
detect early vascular disease in patients at risk for PAH. This finding is in line with the 
elevated PVR and TPG in SSc patients with mildly elevated mPAP, which has already been 
found in a retrospective study of Kovacs et al 2014(6).  
A reduced PAC increases RV pulsatile workload (33) and can lead to RV dysfunction and 
failure. (34, 35). PAC in PAH patients was a stronger predictor of prognosis and response to 
therapy than PVR alone (36-39).  
 
Myocardial function in SSc 
RV-PA uncoupling requires pulmonary vascular disease, reduced RV output reserve or both. 
SSc patients show myocardial involvement even in the absence of PH. Hsu et al showed that 
patients with SSc who do not yet have resting PAH also exhibit abnormal sarcomere function 
due to reduced maximal calcium-activated tension and abnormal increase in calcium 













sensitivity (42). This depressed RV output reserve was also observed in manifest SSc-PAH 
compared to idiopathic PAH (43,28). 
Beside a possible early pulmonary vascular disease indicated by reduced PAC, patients with 
mildly elevated pulmonary arterial pressures in SSc might also be affected by impaired 
myocardial contractility and might therefore be more affected in their exercise capacity, 
symptom load and quality of life.   
 
Overlap of mPAP 21-24mmHg and exercise induced PH 
A resting mPAP 21-24mmHg is above the upper limit of normal but below the criteria of 
manifest PH. Exercise PH is defined as mPAP >30mmHg and total pulmonary resistance 
(TPR) >3 WU (44). Lau et al showed a high overlap of mPAP 21-24mmHg with exercise PH 
with 86% in an at-risk population that was nearly twice as high as the group with mPAP 
<21mmHg (45). This overlapping population was associated with worse functional capacity 
(45), increased progression to resting PH (11) and survival (46, 6). Oliveira et al found that 
exercise PH is most frequently found in mPAP 21-24mmHg and is reducing exercise 
capacity similar to resting PH (47). Our group with mPAP <21mmHg at rest fulfilled the 
criteria for exercise PH in 22 of 72 patients (30.6%) vs. 11 of 14 patients (78.6%) in the group 
with mPAP 21-24mmHg and is in line with the observation of Oliveira et al 2017. However, in 
our study, regression and correlation analysis revealed a significant correlation of PAC at 
rest with 6MWD (R=0.448, p<0.001), Δ cardiac output (R=0.227, p=0.018) and a trend with Δ 
cardiac index (R=0.178, p=0.064) (Figure 2). This supports the hypothesis that PAC and RV 
output reserve play another important role apart from exercise induced PH in exercise 
limitation of SSc patients with mPAP 21-24mmHg. 
 
Early treatment as future strategy 
The described changes in RV function during exercise and pulmonary haemodynamics at 
rest and during exercise in patients with mildly elevated mPAP raise the question whether 
targeted PAH therapy could enhance these impairments and would be justified in these 













patients. In our study, those patients with reduced PAC may already be manifesting 
increased resting PVR, which supports the idea of an early targeted treatment.  In a pilot 
study, bosentan was safe and effective in patients with SSc and mildly elevated mPAP (40). 
Larger clinical trials with relevant outcome measures are needed to define the appropriate 
indication, safety and tolerability of early treatment.  
 
Study Limitations 
The study results may be influenced by the rather small sample size. As not all patients 
reached high workloads, we only reported values up to 75 Watts. Furthermore, the 
presentation of CI and TPG for each workload is an approximation and may be distorted, as 
different peak workload levels were reached.  
The method we used to calculate PAC may overestimate compliance as it does not account 
for blood flow from the pulmonary circulation into the capillary bed during systole (17). Thus, 
the true reduction of PAC in patients with mildly elevated mPAP may be even higher.  
Patients with mildly elevated mPAP had higher values of resting systolic blood pressure than 
those with normal mPAP. However, the systolic blood pressure at peak workload was not 
significantly higher than that of the normal mPAP group. Furthermore, PAWP during exercise 
did not significantly differ between groups. This indicates that systemic blood pressures were 
no explanation for the reduced CI increase during exercise in patients with mildly elevated 
mPAP. 
Data from 2D echo under exercise would have been helpful for interpretation of the results 
but were not part of the initial protocol. 
 
Conclusion 
The results of this study suggest that impaired 6MWD and exercise capacity in SSc-patients 
with mildly elevated mPAP (and normal RV function at rest) might be caused by reduced 
PAC and reduced RV output reserve (reduced RV output during exercise). These findings 













give further evidence for mildly elevated mPAP reflecting an early stage of pulmonary 
vascular disease and RV dysfunction. Screening of SSc-patients using right heart catheter at 
rest and during exercise may lead to an identification of early pulmonary vascular disease. 
Further studies are needed to evaluate if it is useful to start PAH targeted medication in SSc 
patients with mildly elevated mPAP. 
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The study flow-chart describes the study cohort, reasons for exclusion and group allocations. 
 
Figure 2 
Pearson’s correlation analysis of PAC vs. 6MWD show a significant correlation of PAC at 
rest with 6MWD. mPAP-values  20mmHg are coded as green dots, mPAP 21-24mmHg are 
coded as orange triangles and mPAP  25mmHg are coded as red squares. 
 
Figure 3 
The slope of CI increase during exercise showed similar values for patients with mildly 
elevated mPAP and manifest PH. For each stage, the p-value of the respective ANOVA 













between the three groups is shown. At 75 Watts, mildly elevated mPAP patients had a 
significantly smaller increase in CI than patients with normal mPAP (t-test p=0.005). 
 
Figure 4 
PAC significantly differed between groups for each workload level (ANOVA each p≤0.01). 
Patients with mildly elevated mPAP had a significantly lower PAC than patients with normal 






























































Figure 2:  Pearson’s correlation analysis of PAC vs. 6MWD 
 
 
 Figure 3:  Cardiac Index increase over workload levels 
 








































































N rest 25 50 75
Normal 72 69 71 49
Mildly elevated 14 14 11 7




















































N rest 25 50 75
Normal 69 66 70 48
Mildly elevated 14 13 10 6
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